News
A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
1don MSN
Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts
Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback